Our
News
Check back on a regualr basis
for futher updates.
VasoDynamics receives PING Innovation Award 2025
VasoDynamics awarded the Innovation of the Year 2025 by the Pharmaceutical Industry Network Group (PING) after its successful clinical trial showing prevention of severe oral mucositis induced by radiotherapy in patients with head and neck cancers.
NG11-2 Phase Ib clinical study in oral mucositis: UK MHRA confirms Scientific Advisory review meeting for June with feedback in late July 2025
NG11-2 Phase Ib clinical study in oral mucositis: UK MHRA confirms Scientific Advisory review meeting for June with feedback in late July 2025
NG11-2 Phase-Ib Clinical Study Results Summary Available
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
NG11-2 Phase-Ib Clinical Study Report Complete
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
New Year’s letter — Looking back on 2024 and our New Year’s Resolutions for 2025
2024 has been a very eventful and fruitful year for VasoDynamics!
VasoDynamics Receives UK-Taiwan Collaborative R&D Grant
VasoDynamics Receives UK-Taiwan Collaborative R&D Grant VasoDynamics receives Grant to Progress Organ-on-Chip Technology with Partner Genenet 25th November 2024 - VasoDynamics Ltd, the pharmaceutical company developing